NASDAQ:ECYT Endocyte Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.99 0.00 (0.00 %) (As of 12/21/2018) Add Compare Share Today's Range$23.99Now: $23.99▼$23.9950-Day Range N/A52-Week Range$2.81Now: $23.99▼$24.00VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/ABeta-0.01 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.Read More HeadlinesPhase 2B TrialFebruary 11, 2021 | benzinga.comGlobal Castrate Resistant Prostate Cancer Pipeline Insight Report 2020 - ResearchAndMarkets.com - Business WireJanuary 12, 2021 | businesswire.comGlobal Castrate Resistant Prostate Cancer Pipeline Insight Report 2020 Featuring Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma & ESSA Pharma - GlobeNewswireJanuary 11, 2021 | globenewswire.comGlobal CAR-T Pipeline Insight Report 2020: Overview, Landscape, Therapeutic Assessment, Current Treatment Scenario and Emerging Therapies - GlobeNewswireDecember 30, 2020 | globenewswire.comScopus BioPharma Announces Appointment of Additional Directors - PRNewswireDecember 29, 2020 | prnewswire.comVBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors - StreetInsider.comOctober 13, 2020 | streetinsider.comGlobal Nuclear Medicine/Radiopharmaceuticals Manufacturing Report 2020-2030: Current Market Landscape and Potential of Companies Having the Xapabilities to Manufacture Radiopharmaceuticals - Yahoo Finance UKOctober 12, 2020 | uk.finance.yahoo.comKey FDA Approvals Paramount Catalyst for Biotech Run Heading Into NovemberSeptember 8, 2020 | bloomberg.comChimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2020 Results - Earnings Call Transcript - Seeking AlphaAugust 10, 2020 | seekingalpha.comLam Research (LRCX) Tops Q4 Earnings and Revenue Estimates - NasdaqJuly 31, 2020 | www.nasdaq.comRetail Opportunity Investments (ROIC) Q2 FFO and Revenues Surpass Estimates - NasdaqJuly 30, 2020 | www.nasdaq.comPilgrim’s Pride Misses Several Key Estimates, But Says June Looks Better - NasdaqJuly 30, 2020 | www.nasdaq.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ECYT Previous Symbol CUSIP29269A10 CIK1235007 Webwww.endocyte.com Phone765-463-7175EmployeesN/AYear FoundedN/ADebt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales28,133.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book12.06Profitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-55,060,000.00 Net Margins-32,296.09% Return on Equity-21.19% Return on Assets-20.55% Miscellaneous Outstanding Shares82,090,000Market Cap$1.97 billion Next Earnings DateN/A OptionableOptionable MarketRank™Overall MarketRank™0.87 out of 5 starsMedical Sector1087th out of 1,957 stocksPharmaceutical Preparations Industry501st out of 771 stocksAnalyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Endocyte. Previous Next 2.7 Community Rank Outperform VotesEndocyte has received 345 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEndocyte has received 287 “underperform” votes. (Add your “underperform” vote.)Community SentimentEndocyte has received 54.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote “Outperform” if you believe ECYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEndocyte does not currently pay a dividend.Dividend GrowthEndocyte does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Endocyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.65% of the stock of Endocyte is held by insiders.Percentage Held by Institutions75.62% of the stock of Endocyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Endocyte are expected to decrease in the coming year, from ($0.64) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Endocyte is -23.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Endocyte is -23.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEndocyte has a P/B Ratio of 12.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive ECYT News and Ratings via Email Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Endocyte (NASDAQ:ECYT) Frequently Asked Questions What stocks does MarketBeat like better than Endocyte? Wall Street analysts have given Endocyte a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Endocyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%. View Endocyte's earnings history. Who are Endocyte's key executives? Endocyte's management team includes the following people: Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)Mr. Michael T. Andriole, Chief Financial Officer (Age 45)Dr. Alison A. Armour, Chief Medical Officer (Age 54)Dr. Christopher P. Leamon, VP of R&D (Age 52)Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70) Who are some of Endocyte's key competitors? Some companies that are related to Endocyte include Johnson & Johnson (JNJ), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Endo International (ENDP). View all of ECYT's competitors. What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO). What is Endocyte's stock symbol? Endocyte trades on the NASDAQ under the ticker symbol "ECYT." What is Endocyte's stock price today? One share of ECYT stock can currently be purchased for approximately $23.99. How much money does Endocyte make? Endocyte has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. What is Endocyte's official website? The official website for Endocyte is www.endocyte.com. Where are Endocyte's headquarters? Endocyte is headquartered at 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. How can I contact Endocyte? Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175. This page was last updated on 2/25/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
